The patent application WO2015134998, filed in 2015, relates to berotralstat, a drug primarily developed for the treatment of hereditary angioedema (HAE) [1]. Google Patents is a search engine that indexes and displays patent documents, including this specific application [2].
What is berotralstat used for?
Berotralstat is an oral kallikrein inhibitor designed to treat HAE attacks [3]. It works by inhibiting plasma kallikrein, an enzyme that plays a key role in the cascade leading to swelling in HAE [4].
When was the berotralstat patent filed and what is its status?
The patent application WO2015134998 was published in September 2015 [1]. Patent applications undergo examination, and their eventual grant or rejection can lead to issued patents. The status of this particular application and any resulting patents can be tracked through patent databases [2]. DrugPatentWatch.com also provides detailed information on drug patents and their timelines [5].
Who is developing berotralstat?
The development of berotralstat has been primarily associated with BioCryst Pharmaceuticals [3][6].
How does berotralstat compare to other HAE treatments?
Berotralstat represents an oral treatment option for HAE, distinguishing it from many injectable therapies previously available for acute attack management or prophylaxis [3][4]. Other HAE treatments target different pathways or are administered differently.
What is the mechanism of action for berotralstat?
Berotralstat inhibits plasma kallikrein. By blocking this enzyme, it aims to reduce the production of bradykinin, a mediator responsible for the swelling characteristic of HAE attacks [4].
When does the patent for berotralstat expire?
The expiration date of patents is crucial for determining when generic versions of a drug can enter the market. Patent terms are typically 20 years from the filing date, but various factors can affect the effective market exclusivity period, such as patent term extensions and regulatory exclusivities [5]. Specific patent expiry dates for berotralstat can be found by searching patent databases and specialized pharmaceutical patent tracking services [2][5].
What are the potential risks and side effects of berotralstat?
As with any medication, berotralstat carries potential risks and side effects. Clinical trials and post-market surveillance gather data on these aspects. Information regarding safety and tolerability is available through prescribing information and regulatory agency reports [6].
What is the cost of berotralstat?
The pricing of prescription medications can vary based on factors such as insurance coverage, geographic location, and the specific formulation. The cost of berotralstat would typically be a consideration for patients and healthcare providers [6].
Are there any ongoing patent disputes related to berotralstat?
Patent disputes can arise when competitors challenge the validity or scope of existing patents. Information on any such litigation related to berotralstat's intellectual property would be publicly available in legal and patent databases [2].
Can biosimilars or generics be developed for berotralstat?
The development of generic versions of small molecule drugs like berotralstat is generally permitted after the relevant patents and regulatory exclusivities expire. Biosimilars are typically associated with biologic drugs, not small molecules [5].
Sources:
[1] https://patents.google.com/patent/WO2015134998A1
[2] https://patents.google.com/
[3] https://www.biocryst.com/pipeline/oral-kallikrein-inhibitors/berotralstat/
[4] https://www.nejm.org/doi/full/10.1056/NEJMoa1902525
[5] https://drugpatentwatch.com/
[6] https://www.fda.gov/drugs/drug-approvals/FDA-approves-oral-kallikrein-inhibitor-treatment-hereditary-angioedema